# RGT-61159

Source: https://onco.cc/drugs/rgt-61159/  
OnCo record `rgt-61159` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RGT-61159 is an experimental small molecule from Rgenta Therapeutics, in phase 1 trials for relapsed or refractory adenoid cystic carcinoma and colorectal cancer.

## Summary

RGT-61159 is a small molecule (oral RNA splicing modulator) from Rgenta Therapeutics. An oral small molecule designed to change the splicing of the MYB transcription factor's RNA, which stops production of the cancer-driving MYB protein. Its furthest stage is phase 1, for relapsed or refractory adenoid cystic carcinoma and colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT06462183 (alone and with lenvatinib) active, not recruiting. Company news page lists a release of 22 October 2026 announcing a successful end-of-phase 2 meeting with the FDA and alignment on a phase 3 design in adenoid cystic carcinoma. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: RGT-61159
- Modality: Small molecule (oral RNA splicing modulator)
- Mechanism: An oral small molecule designed to change the splicing of the MYB transcription factor's RNA, which stops production of the cancer-driving MYB protein.

## Sources

- Rgenta Therapeutics: prnewswire.com: https://www.prnewswire.com/news-releases/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1ab-clinical-trial-of-rgt-61159-an-oral-small-molecule-targeting-myb-in-adenoid-cystic-carcinoma-acc-and-colorectal-cancer-crc-302269345.html
- Rgenta Therapeutics: rgentatx.com: https://www.rgentatx.com/news
- Rgenta Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06462183
- ClinicalTrials.gov: trials of RGT-61159: https://clinicaltrials.gov/search?intr=RGT-61159

## Connected records

- cancers: [Adenoid cystic carcinoma](https://onco.cc/cancers/adenoid-cystic-carcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [MYB](https://onco.cc/targets/myb/)
- companies: [Rgenta Therapeutics](https://onco.cc/companies/rgenta-therapeutics/)
- trials: [Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)](https://onco.cc/trials/nct06462183/)

---
JSON: https://onco.cc/api/v1/entities/rgt-61159.json